Deceased Organ Donor HTLV Screening Practices Postelimination of Universal Screening in the United States
Open Access
- 17 September 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 10 (10) , e1707
Abstract
Background.: In the United States, universal screening for human T-lymphotropic virus (HTLV) in deceased organ donors was discontinued in 2009. Since then, the transplant guideline suggests considering targeted screening. However, the outcomes of this change in HTLV screening have not been evaluated. Methods.: Using the Organ Procurement and Transplantation Network database between 2010 and 2022, we analyzed the HTLV antibody screening frequency and seroprevalence in potential deceased organ donors and their correlations with HTLV infection risks, including race and high-risk behaviors for blood-borne pathogen infection. Although targeted screening has not been established for HTLV, we hypothesized that screening rates should correlate with the proportions of donors with infection risk if screening is targeted. We also evaluated the organ utilization of HTLV-seropositive donors. Results.: Of 130 284 potential organ donors, 22 032 (16.9%) were tested for HTLV antibody. The proportion of donors tested for HTLV varied between Organ Procurement Organizations (median [interquartile range], 3.8% [1.0%–23.2%]; range, 0.2%–99.4%) and was not correlated to HTLV infection risks. There were 48 seropositive donors (0.22%), and at least 1 organ from 42 of these donors (87.5%) was transplanted. The number of organs recovered and transplanted per donor was significantly lower in HTLV-seropositive than in HTLV-negative donors (recovered, 2 [2–3] versus 3 [3–5], P < 0.001; transplanted, 2 [1–3] versus 3 [2–4], P < 0.001). However, HTLV-1 infection was not attributed as the cause of nonrecovery except for only 1 HTLV-seropositive donor. Conclusions.: HTLV screening practices varied across the United States. Our findings suggest that targeted screening was not performed after the elimination of universal screening.Keywords
This publication has 28 references indexed in Scilit:
- Integrated molecular and immunological features of human T-lymphotropic virus type 1 infection and disease progression to adult T-cell leukaemia or lymphomaThe Lancet Haematology, 2023
- An update on human T-cell leukemia virus type I (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) focusing on clinical and laboratory biomarkersPharmacology & Therapeutics, 2021
- Risk of Human T-Cell Leukemia Virus Type 1 Infection in Kidney TransplantationNew England Journal of Medicine, 2019
- Human T‐lymphotropic virus type 1 infection and solid organ transplantationReviews in Medical Virology, 2018
- HTLV-1 associated myelopathy after renal transplantationJournal of Clinical Virology, 2015
- Seroprevalence and Demographic Determinants of Human T-Lymphotropic Virus Type 1 and 2 Infections Among First-Time Blood Donors--United States, 2000-2009The Journal of Infectious Diseases, 2013
- Delayed Seroconversion and Rapid Onset of Lymphoproliferative Disease After Transmission of Human T-Cell Lymphotropic Virus Type 1 From a Multiorgan DonorClinical Infectious Diseases, 2013
- Rapid development of subacute myelopathy in three organ transplant recipients after transmission of human T-cell lymphotropic virus Type I from a single donorTransplantation, 2003
- Trends in Incidence and Prevalence of Major Transfusion-Transmissible Viral Infections in US Blood Donors, 1991 to 1996JAMA, 2000
- Seroprevalence of HTLV-I and HTLV-II among Intravenous Drug Users and Persons in Clinics for Sexually Transmitted DiseasesNew England Journal of Medicine, 1992